Smetana Keaton S, Roe Neil A, Doepker Bruce A, Jones G Morgan
Department of Clinical Pharmacy, The Ohio State University Wexner Medical Center, Columbus (Drs Smetana and Doepker); Department of Pharmacy, Baptist Health Medical Center, Little Rock, Arkansas (Dr Roe); Department of Pharmacy, Methodist University Hospital, Memphis, Tennessee (Dr Jones); and Department of Clinical Pharmacy, Neurology, and Neurosurgery, The University of Tennessee Health Science Center, Memphis (Dr Jones).
Crit Care Nurs Q. 2017 Oct/Dec;40(4):323-343. doi: 10.1097/CNQ.0000000000000171.
The use of continuous infusion neuromuscular blocking agents remains controversial. The clinical benefit of these medications may be overshadowed by concerns of propagating intensive care unit-acquired weakness, which may prolong mechanical ventilation and impair the inability to assess neurologic function or pain. Despite these risks, the use of neuromuscular blocking agents in the intensive care unit is indicated in numerous clinical situations. Understanding pharmacologic nuances and clinical roles of these agents will aid in facilitating safe use in a variety of acute disease processes. This article provides clinicians with information regarding pharmacologic differences, indication for use, adverse effects, recommended doses, ancillary care, and monitoring among agents used for continuous neuromuscular blockade.
持续输注神经肌肉阻滞剂的应用仍存在争议。这些药物的临床益处可能会因对重症监护病房获得性肌无力蔓延的担忧而被掩盖,这可能会延长机械通气时间,并影响对神经功能或疼痛的评估能力。尽管存在这些风险,但在众多临床情况下,重症监护病房仍会使用神经肌肉阻滞剂。了解这些药物的药理学细微差别和临床作用,将有助于在各种急性疾病过程中安全使用。本文为临床医生提供了有关用于持续神经肌肉阻滞的药物之间的药理学差异、使用指征、不良反应、推荐剂量、辅助护理和监测等方面的信息。